AU2013331412A1 - Apparatus for extracorporeal cellular therapy of lung or other organ - Google Patents
Apparatus for extracorporeal cellular therapy of lung or other organ Download PDFInfo
- Publication number
- AU2013331412A1 AU2013331412A1 AU2013331412A AU2013331412A AU2013331412A1 AU 2013331412 A1 AU2013331412 A1 AU 2013331412A1 AU 2013331412 A AU2013331412 A AU 2013331412A AU 2013331412 A AU2013331412 A AU 2013331412A AU 2013331412 A1 AU2013331412 A1 AU 2013331412A1
- Authority
- AU
- Australia
- Prior art keywords
- organ
- cells
- lung
- vivo
- resident cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000000056 organ Anatomy 0.000 title claims abstract description 31
- 210000004072 lung Anatomy 0.000 title claims abstract description 25
- 238000002659 cell therapy Methods 0.000 title description 4
- 238000000034 method Methods 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 43
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 7
- 230000009286 beneficial effect Effects 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 4
- 238000002054 transplantation Methods 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 3
- 210000000130 stem cell Anatomy 0.000 claims description 3
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 230000017531 blood circulation Effects 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 230000036770 blood supply Effects 0.000 claims 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims 2
- 239000011148 porous material Substances 0.000 abstract description 3
- 238000011282 treatment Methods 0.000 abstract description 3
- 230000004087 circulation Effects 0.000 abstract description 2
- 238000004891 communication Methods 0.000 abstract description 2
- 239000007788 liquid Substances 0.000 abstract description 2
- 239000011159 matrix material Substances 0.000 abstract description 2
- 210000001519 tissue Anatomy 0.000 description 14
- 239000003102 growth factor Substances 0.000 description 11
- 102000004127 Cytokines Human genes 0.000 description 9
- 108090000695 Cytokines Proteins 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 7
- 239000012530 fluid Substances 0.000 description 6
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 4
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 230000010412 perfusion Effects 0.000 description 4
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 3
- 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 description 3
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 208000007204 Brain death Diseases 0.000 description 2
- -1 Gal-i Proteins 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
- 229960002986 dinoprostone Drugs 0.000 description 2
- 230000003511 endothelial effect Effects 0.000 description 2
- 210000003038 endothelium Anatomy 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000005265 lung cell Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 102100022464 5'-nucleotidase Human genes 0.000 description 1
- 102000009088 Angiopoietin-1 Human genes 0.000 description 1
- 108010048154 Angiopoietin-1 Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 208000034706 Graft dysfunction Diseases 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 description 1
- 108010024164 HLA-G Antigens Proteins 0.000 description 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 102100020880 Kit ligand Human genes 0.000 description 1
- 101710177504 Kit ligand Proteins 0.000 description 1
- 102100032352 Leukemia inhibitory factor Human genes 0.000 description 1
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
- 208000004530 Primary Graft Dysfunction Diseases 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 101710113649 Thyroid peroxidase Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000008649 adaptation response Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000004859 alveolar capillary barrier Effects 0.000 description 1
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 210000001601 blood-air barrier Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000007360 epithelial dysfunction Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 108700014844 flt3 ligand Proteins 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000005399 mechanical ventilation Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 239000000082 organ preservation Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000003331 prothrombotic effect Effects 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 210000003492 pulmonary vein Anatomy 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/14—Mechanical aspects of preservation; Apparatus or containers therefor
- A01N1/142—Apparatus
- A01N1/143—Apparatus for organ perfusion
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
- A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1891—Angiogenesic factors; Angiogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/196—Thrombopoietin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Environmental Sciences (AREA)
- Wood Science & Technology (AREA)
- Dentistry (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Biophysics (AREA)
- Physiology (AREA)
- External Artificial Organs (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261713832P | 2012-10-15 | 2012-10-15 | |
| US61/713,832 | 2012-10-15 | ||
| PCT/US2013/065033 WO2014062669A1 (en) | 2012-10-15 | 2013-10-15 | Apparatus for extracorporeal cellular therapy of lung or other organ |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2013331412A1 true AU2013331412A1 (en) | 2015-06-04 |
Family
ID=50488692
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2013331412A Abandoned AU2013331412A1 (en) | 2012-10-15 | 2013-10-15 | Apparatus for extracorporeal cellular therapy of lung or other organ |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20150296770A1 (enExample) |
| EP (1) | EP2906232A4 (enExample) |
| JP (1) | JP2015536322A (enExample) |
| AU (1) | AU2013331412A1 (enExample) |
| WO (1) | WO2014062669A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102337954B1 (ko) * | 2018-08-16 | 2021-12-10 | 차의과학대학교 산학협력단 | 뇌졸중 치료용 조성물 및 이를 스크리닝하는 방법 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2835629B2 (ja) * | 1989-05-18 | 1998-12-14 | ザ リージェンツ オブ ザ ユニヴァーシティ オブ ミネソタ | バイオリアクター装置 |
| ATE373079T1 (de) * | 1999-06-21 | 2007-09-15 | Gen Hospital Corp | Zellkultursysteme und verfahren für einrichtungen zur organunterstützung |
| RU2006144851A (ru) * | 2004-06-15 | 2008-06-20 | Бакстер Интернэшнл Инк. (Us) | Применение терапевтических средств ex-vivo в виде твердых микрочастиц |
| US20120064050A1 (en) * | 2009-02-04 | 2012-03-15 | Yale University | Tissue Engineering of Lung |
| AU2011250989B2 (en) * | 2010-05-12 | 2015-05-07 | Scinus Cell Expansion B.V. | Cell-culture-bag |
| US9534204B2 (en) * | 2010-10-05 | 2017-01-03 | Aal Scientifics, Inc. | Human lung stem cells and uses thereof |
| EP3578522A1 (en) * | 2010-12-06 | 2019-12-11 | Pall Corporation | Continuous processing methods for biological products |
| WO2012166903A1 (en) * | 2011-06-02 | 2012-12-06 | President And Fellows Of Harvard College | Methods and uses for ex vivo tissue culture systems |
-
2013
- 2013-10-15 EP EP13847671.8A patent/EP2906232A4/en not_active Withdrawn
- 2013-10-15 AU AU2013331412A patent/AU2013331412A1/en not_active Abandoned
- 2013-10-15 WO PCT/US2013/065033 patent/WO2014062669A1/en not_active Ceased
- 2013-10-15 JP JP2015537771A patent/JP2015536322A/ja active Pending
- 2013-10-15 US US14/435,629 patent/US20150296770A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2015536322A (ja) | 2015-12-21 |
| WO2014062669A1 (en) | 2014-04-24 |
| EP2906232A4 (en) | 2016-09-28 |
| EP2906232A1 (en) | 2015-08-19 |
| US20150296770A1 (en) | 2015-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9629358B2 (en) | Administration and monitoring of nitric oxide in ex vivo fluids | |
| Matheis | New technologies for respiratory assist | |
| CN114375945A (zh) | 用于供体肺的离体机器灌注的器官护理溶液 | |
| JP7419299B2 (ja) | 機能的肺血管床の再生 | |
| López-Martínez et al. | Normothermic machine perfusion systems: where do we go from here? | |
| US12052987B2 (en) | Administration and monitoring of nitric oxide in ex vivo fluids | |
| US20240138399A1 (en) | Methods to improve organ viability | |
| US12048303B2 (en) | Systems and methods to perfuse isolated tissue | |
| CN109985064B (zh) | 间充质干细胞分泌提取物的用途、间充质干细胞分泌提取物及其制备方法 | |
| AU2013331412A1 (en) | Apparatus for extracorporeal cellular therapy of lung or other organ | |
| Robicsek et al. | Transplantation of “live” hearts | |
| CN104307064A (zh) | 一种肢体局部给药和透析装置及其应用 | |
| Kubat | The importance of platelet-derived mitochondrial transplantation in ischemic heart disease: a clinical study | |
| RU2535036C1 (ru) | Способ презервирования миокарда при трансплантации | |
| Rostron et al. | Donor management | |
| ES2923925T3 (es) | Formulaciones de células mononucleares de sangre periférica sometidas a hipoxia | |
| Long et al. | New horizons in lung transplantation | |
| Forgie | Refinement of Methodology in Ex-Situ Lung Perfusion | |
| Thingnam | Beating Heart in a Box: The Future of Cardiac Transplant | |
| Nakao et al. | Recombinant Thrombomodulin Reduce Histone-Induced Rat Lung Transplant Model of Primary Graft Dysfunction | |
| Krueger et al. | Ex vivo lung perfusion | |
| JP2007217283A (ja) | 血管新生促進剤および血管新生療法 | |
| REGA et al. | DIRK VAN RAEMDONCK | |
| Kolettis et al. | Chronic skeletal muscle ischemia preserves coronary | |
| ATTENUATES | 456 PROGNOSTIC VALUE OF INTRAOPERATIVE RENAL TISSUE OXYGENATION MEASUREMENT ON EARLY RENAL TRANSPLANT FUNCTION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |